ATE365550T1 - Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie - Google Patents

Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie

Info

Publication number
ATE365550T1
ATE365550T1 AT99911365T AT99911365T ATE365550T1 AT E365550 T1 ATE365550 T1 AT E365550T1 AT 99911365 T AT99911365 T AT 99911365T AT 99911365 T AT99911365 T AT 99911365T AT E365550 T1 ATE365550 T1 AT E365550T1
Authority
AT
Austria
Prior art keywords
diabetic retinopathy
genistein
treatment
protein kinase
kinase inhibitor
Prior art date
Application number
AT99911365T
Other languages
English (en)
Inventor
Juan Jr Eugene De
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09041931 external-priority patent/US5919813C1/en
Priority claimed from US09/042,440 external-priority patent/US5980929A/en
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of ATE365550T1 publication Critical patent/ATE365550T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)
AT99911365T 1998-03-13 1999-03-12 Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie ATE365550T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09041931 US5919813C1 (en) 1998-03-13 1998-03-13 Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
US09/042,440 US5980929A (en) 1998-03-13 1998-03-13 Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation

Publications (1)

Publication Number Publication Date
ATE365550T1 true ATE365550T1 (de) 2007-07-15

Family

ID=26718704

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99911365T ATE365550T1 (de) 1998-03-13 1999-03-12 Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie

Country Status (7)

Country Link
EP (2) EP1061913B1 (de)
JP (2) JP2002506028A (de)
AT (1) ATE365550T1 (de)
AU (1) AU756515B2 (de)
CA (1) CA2321560C (de)
DE (1) DE69936381T2 (de)
WO (1) WO1999045920A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1131073E (pt) * 1998-11-23 2004-03-31 Novartis Ag Uso de derivados de estaurosporina para o tratamento de doencas oculares neovasculares
US6399107B1 (en) 1998-12-22 2002-06-04 Alcon Laboratories, Inc. Use of inhibitors of gag synthesis for the treatment of corneal haze
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
CA2373178C (en) * 1999-05-07 2013-07-02 Johns Hopkins University School Of Medicine The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
TR200201047T2 (tr) 1999-10-21 2002-07-22 Alcon, Inc. İlaç verme vasıtası.
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US7943162B2 (en) 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
AU775149B2 (en) 1999-10-21 2004-07-22 Alcon Inc. Sub-tenon drug delivery
JP2003530309A (ja) * 1999-10-26 2003-10-14 イミューソル インコーポレイテッド 増殖性皮膚疾患又は増殖性眼疾患を治療するリボザイム療法
PT1385452E (pt) 2001-07-23 2006-12-29 Alcon Inc Dispositivo de administração de fármacos oftálmicos
DE60217679T2 (de) 2001-07-23 2007-10-25 Alcon Inc. Vorrichtung zur freisetzung eines ophthalmischen arzneimittels
AU2002359635A1 (en) * 2001-12-05 2003-06-17 Mitokor, Inc. Use of polycyclic phenolic compounds for the treatment of opthalmic diseases
GB0302882D0 (en) * 2003-02-07 2003-03-12 Univ Cardiff Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
EP1648926B1 (de) 2003-05-02 2013-07-03 Centre National De La Recherche Scientifique (Cnrs) Glut-1 als rezeptor für htlv-hüllen und dessen verwendungen
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
JP2007505932A (ja) 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050261197A1 (en) * 2004-05-19 2005-11-24 Henry Aoki Coffee bean extract, method of extraction and composition containing the same
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
KR101478164B1 (ko) 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US20080181972A1 (en) * 2007-01-29 2008-07-31 Valentina Amico Compositions and Methods for Maintaining, Strengthening, Improving, or Promoting Eye Health
US9482677B2 (en) 2008-02-27 2016-11-01 Scios Inc. Method, composition and device for sampling natriuretic peptides in a biological fluid
WO2010079208A1 (en) 2009-01-09 2010-07-15 Centre National De La Recherche Scientifique New receptor binding ligands, their use in the detection of cells with biological interest
US8372036B2 (en) 2009-05-06 2013-02-12 Alcon Research, Ltd. Multi-layer heat assembly for a drug delivery device
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
HK1204988A1 (en) * 2012-02-22 2015-12-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2064101T3 (es) * 1990-04-02 1995-01-16 Pfizer Compuestos de acido bencilfosfonico inhibidores de la quinasa de tirosina.
EP0654024A1 (de) * 1992-08-06 1995-05-24 Warner-Lambert Company 2-thioindole (selenoindole) und verwandte disulfide (selenide), die tyrosin proteinkinase inhibitoren sind, und ihre verwendung als anti-tumor mittel
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5710173A (en) * 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
US5834513A (en) * 1996-04-25 1998-11-10 Avon Products, Inc. Oxa diacids and related compounds for treating skin conditions

Also Published As

Publication number Publication date
DE69936381D1 (de) 2007-08-09
CA2321560C (en) 2007-05-22
JP2010168389A (ja) 2010-08-05
WO1999045920A2 (en) 1999-09-16
AU756515B2 (en) 2003-01-16
AU3001999A (en) 1999-09-27
WO1999045920A3 (en) 1999-10-21
EP1061913B1 (de) 2007-06-27
DE69936381T2 (de) 2007-10-31
EP1806135A2 (de) 2007-07-11
EP1061913A2 (de) 2000-12-27
EP1806135A3 (de) 2010-11-24
CA2321560A1 (en) 1999-09-16
JP2002506028A (ja) 2002-02-26

Similar Documents

Publication Publication Date Title
DE69936381D1 (de) Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie
ES2152556T3 (es) Composiciones que contienen derivados del acido hidroperoxieicosatetraenoico y procedimientos de utilizacion en el tratamiento de trastornos de la sequedad ocular.
FR18C1012I2 (fr) Derives de staurosporine inhibiteurs de l'activite tyrosine kinase du recepteur flt3
ATE323482T1 (de) Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
ATE329596T1 (de) Phthalazinderivate zur behandlung von entzündlicher erkrankungen
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
BR0213738A (pt) proteìnas morfogênicas ósseas (bmp), receptores de bmp e proteìnas de ligação de bmp e seu uso no diagnóstico e no tratamento de glaucoma
DE60144277D1 (de) Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
FI970489L (fi) Paikallisesti käytettäviä silmälääkekoostumuksia, jotka sisältävät doksepiinijohdoksia ja soveltuvat allergisten silmäsairauksien hoitoon
PT950057E (pt) Enantiomeros de 3-piridilo e sua utilizacao como analgesicos
DE69814394D1 (de) Verwendung von levobupivacain
EA200001247A1 (ru) N-связанные сульфонамиды n-гетероциклических карбоновых кислот или изостеры карбоновых кислот
DE69613386D1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
EE200100188A (et) Optiliselt aktiivne püridüül-4H-1,2,4-oksadiasiini derivaat ja selle kasutamine vaskulaarsete haiguste ravis
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
ATE359774T1 (de) Taurinderivate verwendbar in der behandlung von netzhauterkrankungen
ATE252387T1 (de) Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties